论文部分内容阅读
目的观察标准化疗联合预激方案序贯双诱导治疗原发初治急性髓系白血病(AML)的疗效和安全性。方法对患者进行标准方案[蒽环类联合阿糖胞苷(Ara-C)]联合预激方案序贯诱导缓解治疗,治疗过程中监测治疗反应及化疗不良反应。结果 15例患者中完全缓解13例,完全缓解率为86.7%。最常见的不良反应为骨髓抑制,其次为感染,以肺部感染最常见(发生率为40.0%)。结论标准联合预激方案序贯双诱导治疗原发初治AML有效且安全。
Objective To observe the efficacy and safety of sequential dual induction of standard chemotherapy combined with pre-stimulation therapy for primary primary acute myeloid leukemia (AML). Methods Patients were treated with a sequential regimen of anthracycline combined with cytarabine (Ara-C) combined with priming regimen to induce sequential remissions. Patients were monitored for treatment response and adverse chemotherapy reactions during the course of treatment. Results Fifteen patients had complete remission in 13 cases, and the complete remission rate was 86.7%. The most common adverse reactions were myelosuppression, followed by infection, with pulmonary infection being the most common (occurrence rate 40.0%). Conclusions The sequential and double-induction of the standard combined priming program is effective and safe for primary treatment of primary AML.